Pdf a comparative pharmacokinetic and pharmacodynamic. Nov 19, 2007 any joy that roche, the swiss pharmaceutical group, may have felt last week at getting approval from the us food and drug administration for mircera was tempered by the fact the drug cannot be sold in the us. Mircera solution for injection in prefilled syringe. When your body does not make enough of this protein because of kidney failure, you can develop a condition called anemia lack of red blood cells. Mircera is an erythropoiesisstimulating agent esa indicated for the treatment of anemia associated with chronic kidney disease ckd in adult patients on dialysis and patients not on dialysis 1.
Roche forced to play waiting game with mircera unless it. Mircera is a longacting erythropoietin receptor activator cera indicated for the treatment of patients with anaemia associated with chronic kidney disease. Download cmi pdf download large text cmi pdf what is in this leaflet. Highlights of prescribing information platinumresistant. Dose conversion ratio in hemodialysis patients switched from. Highlights of prescribing information these highlights do not include all the information needed to use mircera safely and effectively. Refer patients who selfadminister mircera to the instructions for use see patient counseling information 17. Rss feeds trends, charts, and maps downloading content for analysis. Mircera, innmethoxy polyethylene glycolepoetin beta. An appeals court has ruled that swiss pharmaceutical giant roche holding ltd. Jan 18, 2010 this observational study will investigate hemoglobin levels and mircera methoxy polyethyleneglycol epoetin beta dose over time in patients with chronic kidney disease, and compare standards of care between centers.
Limitations of use mircera is not indicated and is not. Esas, when administered to target haemoglobin of 120. Roche cannot respond to questions about general medical information or questions regarding your personal medical condition. Epo is produced in the body by the kidneys and is used to regulate red blood cell production. Mircera works like the human protein called erythropoietin to help your body make more rbcs. Dec 18, 2019 one prefilled syringe contains 30 micrograms of methoxy polyethylene glycolepoetin beta at a concentration of 100 microgramsml. Continuous erythropoietin receptor activator cera or methoxypolyethylene glycolepoetine, known by the brand name mircera f. Prior authorization is required to ensure the safe, clinically appropriate and cost effective use of mircera while maintaining optimal therapeutic outcomes.
Ro0503821 mircera may 2015 2 product information feenglish 2. By using this site, you agree that we may store and access cookies on your device. Roche viforchugai is a novel erythropoiesisstimulating agent esa designated as a continuous erythropoietin receptor activator. This study will assess the efficacy and safety of intravenous iv mircera given as. Roche mircera methoxy polyethylene glycolepoetin beta. A study of intravenous mircera for the treatment of anemia in.
Mircera, roche, basel, switzerland is a novel agent that has a. Mircera erythropoietin beta or epo is a naturally occurring protein hormone. Roche will keep a record of the personal data that you provide for the purpose of responding to your inquiry, to follow up on such requests, to maintain the information in the roche global pharmacovigilance database, the roche product complaint database and the medical information database for reference, whichever is applicable, and to comply. Patients suffering from anemia or chronic renal failure are legally allowed to use this form medically, it is proven that this product effectively stimulates and maintains. Roche holding ag said wednesday that it would begin marketing its anemia drug mircera in the united states as soon as it receives food and drug administration approval, despite an ongoing patent. Mircera solution for injection in prefilled syringe patient information leaflet pil by roche products limited. The safety and efficacy of mircera in patients under 18 years of age have not been established 1. Pdf a comparative pharmacokinetic and pharmacodynamic study.
Webmd provides common contraindications for mircera injection. Mircera is not indicated and is not recommended for use in the treatment of anemia due to cancer chemotherapy, or as a substitute for rbc transfusions in patients who require immediate correction of anemia. Mircera methoxy polyethylene glycolepoetin beta rationale for inclusion in pa program. Mircera methoxy polyethylene glycolepoetin beta drug medicine. Dailymed mircera methoxy polyethylene glycolepoetin beta. Mircera methoxy polyethylene glycolepoetin beta policy. Subsequently, mircera serum concentrations declined with an apparent mean halflife of approximately 121 to 147 hours geometric mean comparable to adults. Use the lowest mircera dose sufficient to reduce the need for red. Hoffmannla roche, basel, switzerland is a continuous erythropoietin receptor activator c. Hoffmannla roche ltd, basel, switzerland, is the first of a new class of longeracting esas designed to correct and maintain hb levels in ckd patients. Pdf costeffectiveness of continuous erythropoietin receptor. Mircera methoxy polyethylene glycolepoetin beta drug. Aug 05, 2019 mircera is a prescription medicine used to treat anemia. Consumer medicine information cmi about mircera methoxy polyethylene glycolepoetin beta intended for persons living in australia.
Data from each patient will be collected over 12 months of mircera therapy. Mircera is not indicated and is not recommended for the treatment of anemia due to cancer chemotherapy. Data from each patient will be collected over 12 months of mircera. Sustainability download center with documents about our high standards, policies and. Roche inks commercialization deal for mircera in u. People with anemia have a lowerthannormal number of rbcs. Roche enters into exclusive license agreement with galenica for the commercialisation of mircera in the united states. One prefilled syringe contains 40 micrograms of methoxy polyethylene glycolepoetin beta at a concentration of 3 microgramsml. This observational study will investigate hemoglobin levels and mircera methoxy polyethyleneglycol epoetin beta dose over time in patients with chronic kidney disease, and compare standards of care between centers. It is the first approved, chemically modified erythropoiesisstimulating agent esa. Mircera is used to reduce or avoid the need for rbc transfusions.
Hcpcs code1 j0887, injection, epoetin beta, 1 microgram, for esrd on dialysis hcpcs code1 j0888, injection, epoetin beta, 1. Nektar therapeutics announces agreement to sell cimzia. Consumer medicine information cmi about mircera methoxy polyethylene. To report suspected adverse reactions, contact roche at. Mircera is a longacting erythropoietin receptor activator cera indicated for. Download mircera koulutusohjelma download document. Mircera with 1step decrease as soon as hgb is 12 for more than 2 months, return to regular hgb testing policy. Rhhby announced today that it has entered into an exclusive licence agreement with galenica for the commercialisation of roche s drug mircera methoxy. Consult smpc for additional information on pediatric use, hepatic impairment, overdose, list of excipients and storage.
In the treatment of anemia due to cancer chemotherapy 1. Contact roche at 18888352555 to perform assays for binding and neutralizing. Find out what health conditions may be a health risk when taken with mircera injection. Roche registration limited, 6 falcon way, shire park, welwyn garden city, al 7 1 tw, uk. Mircera is not indicated and is not recommended for use. A comparative pharmacokinetic and pharmacodynamic study of two novel cuban pegylated rhuepo versus mircera and iorepocim. Treatment with mircera has to be initiated under the supervision of a healthcare professional. Mircera is a prescription medicine used to treat anemia. Mircerais used to treat anemia caused by chronic kidney disease. Mircera methoxy polyethylene glycolepoetin beta solution for injection. Mircera solution for injection in prefilled syringe patient. This page is provided as a contact service and does not replace the advice of a physician.
Waiting game continues with mircera launch evaluate. So, the displacement of a hydrogen atom still meant that roches mircera infringed on amgens patents. This consumer medicine information cmi is intended for persons living in australia. Roche has been able to launch mircera in the us since july 1, but as yet there is no sign of the drug on pharmacy shelves. A doseranging study of mircera was terminated early because of more deaths among. These highlights do not include all the information needed to use mircera. Roche wins safe harbor for mircera tests for now law360. Methoxy polyethylene glycolepoetin beta roche adisinsight.
This leaflet answers some common questions about mircera. Australian product information mircera methoxy polyethylene. Roche products pty limited abn 70 000 2 865 4 10 inman road dee why nsw 2099 customer enquiries. Pdf background erythropoiesisstimulating agents esas are the mainstay of anemia therapy. Methoxy polyethylene glycolepoetin beta for anemia with chronic. Oceane cohorte mircera patients nondialyses, a national, multicenter, longitudinal. Oct 31, 20 affirm aranesp efficiency relative to mircera was a retrospective, multisite, observational study designed to estimate the population mean maintenance dose conversion ratio dcr.
Mircera has not been shown to improve quality of life, fatigue, or patient wellbeing. Highlights of prescribing information these highlights do not include all the information needed to use avastin safely and effectively. Epoetin beta and methoxy polyethylene glycol is a manmade form of a protein normally produced by the kidneys that helps your body produce red blood cells. Mircera is a solution for injection in prefilled syringe. At steady state following the third iv administration of mircera the maximum observed exposures were a geometric mean cmax of 66. Administer mircera as an intravenous injection at the dose in micrograms based on the total weekly esa dose at the time of conversion see table 2. At the same time, trends in anaemia management are oriented towards simplifying treatment by allowing a longer interval between doses. Last month, biotech giant amgen successfully proved that several of its patents, including composition of matter patents for its erythropoietin epo drugs, had been infringed by roche. Mircera methoxy polyethylene glycolepoetin beta injection, solution vifor international inc.
Administer mircera intravenously once every 4 weeks to pediatric patients ages 5 to 17 years whose hemoglobin level has been stabilized by treatment with an esa. Mircera fda prescribing information, side effects and uses. Jun 24, 2019 mircera injection contains epoetin beta and methoxy polyethylene glycol. Mircera is an erythropoiesis stimulating agent esa that binds to progenitor stem cells and stimulates the production and differentiation of red blood cells rbcs. Mircera comes in prefilled syringes with laminated plunger stopper and tip cap with one needle 27g12. Name of the medicine methoxy polyethylene glycolepoetin beta 2. Rhhby enters into an exclusive license agreement with bern, switzerlandbased galenica for the commercialization of mircera methoxy polyethylene glycolepoetin beta in the u. Use the lowest mircera dose sufficient to reduce the need for red blood cell rbc transfusions. Mircera injection contains epoetin beta and methoxy polyethylene glycol. Methoxy polyethylene glycolepoetin beta r 744, an erythropoiesisstimulant, is being developed by roche for the treatment of anaemia associated with chronic.
The solution is clear, colourless to slightly yellowish and free of visible particles. The drug was originally available in europe and japan, and launched in the us in late 2015. Methoxy polyethylene glycolepoetin beta is the active ingredient of a drug marketed by hoffmannla roche under the brand name mircera. Anemia control in kidney transplant patients treated with. Any joy that roche, the swiss pharmaceutical group, may have felt last week at getting approval from the us food and drug administration for mircera was tempered by the fact the drug cannot be sold in the us. Titrate mircera per the following table for patients who have a mircera order and had not been changed in the last 4 weeks. Mircera, like other esas, is a growth factor that primarily stimulates red blood cell rbc production. The indications below including fdaapproved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.
1346 759 579 1376 328 926 764 520 551 1016 500 1345 218 1445 162 449 254 707 1157 143 1483 632 72 188 1368 1069 624 144 497 720 389 1161 691 568 406